Mesa Laboratories (NASDAQ:MLAB) Announces Earnings Results, Misses Expectations By $2.14 EPS

Mesa Laboratories (NASDAQ:MLAB) posted its earnings results on Monday. The medical instruments supplier reported $0.49 EPS for the quarter, missing the consensus estimate of $2.63 by ($2.14), FiscalAI reports. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The business had revenue of $60.14 million for the quarter, compared to analyst estimates of $60.87 million.

Mesa Laboratories Stock Performance

Shares of Mesa Laboratories stock traded down $1.03 on Monday, reaching $101.62. The stock had a trading volume of 103,018 shares, compared to its average volume of 145,376. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72. The business’s 50-day moving average price is $100.33 and its two-hundred day moving average price is $95.20. The stock has a market cap of $569.07 million, a P/E ratio of 84.68 and a beta of 0.92. Mesa Laboratories has a fifty-two week low of $58.83 and a fifty-two week high of $113.99.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s payout ratio is presently 53.33%.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mesa Laboratories presently has an average rating of “Reduce” and an average price target of $94.00.

Insider Activity at Mesa Laboratories

In other Mesa Laboratories news, CAO Lyndsey Elizabeth Crennen sold 442 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares in the company, valued at $180,790. This represents a 17.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO John Sakys sold 2,827 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares in the company, valued at approximately $1,770,757.50. This represents a 12.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 8,277 shares of company stock worth $770,122. 2.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Squarepoint Ops LLC bought a new stake in shares of Mesa Laboratories during the fourth quarter valued at approximately $216,000. Mariner LLC bought a new position in Mesa Laboratories in the fourth quarter worth $260,000. State Board of Administration of Florida Retirement System acquired a new stake in Mesa Laboratories during the fourth quarter worth $201,000. Jacobs Levy Equity Management Inc. bought a new stake in Mesa Laboratories in the 3rd quarter valued at $258,000. Finally, Numerai GP LLC bought a new stake in Mesa Laboratories in the 3rd quarter valued at $242,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.